Limits...
Safety and effectiveness of vibration massage by deep oscillations: a prospective observational study.

Kraft K, Kanter S, Janik H - Evid Based Complement Alternat Med (2013)

Bottom Line: Primary outcome parameters were safety and tolerability (5-level Likert scale (1 = very good)) (after each treatment session and at control visit).Tolerability was rated as 1.8 (95% confidence interval: 1.53; 2.07).In conclusion, deep oscillation massage is safe and well tolerated in patients with FMS and might improve symptoms and quality of life rather sustained.

View Article: PubMed Central - PubMed

Affiliation: Chair of Complementary Medicine, Center of Internal Medicine, Rostock University Medicine, Ernst-Heydemann-Straße 6, 18057 Rostock, Germany.

ABSTRACT
The objective of this study is to assess the safety of treatment with vibration massage using a deep oscillation device and the effects on symptom severity and quality of life in patients with primary fibromyalgia syndrome (FMS). Outpatients with FMS performed an observational prospective study with visits 2-4 weeks after the last treatment (control) and after further 2 months (follow-up). Patients were treated with 10 sessions of 45 min deep oscillation massage, 2/week. Primary outcome parameters were safety and tolerability (5-level Likert scale (1 = very good)) (after each treatment session and at control visit). Secondary outcome parameters were symptom severity (Fibromyalgia Impact Questionnaire (FIQ), pain) and quality of life (SF-36). Seventy patients (97.1% females) were included. At control visit, 41 patients (58.6%) reported 63 mild and short-lasting adverse events, mainly worsening of prevalent symptoms such as pain and fatigue. Tolerability was rated as 1.8 (95% confidence interval: 1.53; 2.07). Symptoms and quality of life were significantly improved at both control and follow-up visits (at least P < 0.01). In conclusion, deep oscillation massage is safe and well tolerated in patients with FMS and might improve symptoms and quality of life rather sustained.

No MeSH data available.


Related in: MedlinePlus

Pain (visual analogue scale (VAS)) before treatment (I1), 2–4 weeks after the last treatment session (I2), and 2 months after I2 (I3); mean and 95% confidence interval (95% CI); I1 versus I2 or versus I3: *P < 0.001; arrow and lines indicate 95% CI of the individually acceptable pain level of the patients.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3814103&req=5

fig3: Pain (visual analogue scale (VAS)) before treatment (I1), 2–4 weeks after the last treatment session (I2), and 2 months after I2 (I3); mean and 95% confidence interval (95% CI); I1 versus I2 or versus I3: *P < 0.001; arrow and lines indicate 95% CI of the individually acceptable pain level of the patients.

Mentions: Compared to I1, mean VAS score (pain) at I2 was reduced by 28.2% and at I3 by 18.8% (P < 0.001; Figure 3, Table 7). The patients' distribution according to the pain severity categories was mild (17.1%), moderate (25.7%), severe (35.7%), and very severe (21.5%) at I1; at I2 and I3, a shift to lower categories was shown (Table 5). At I1, the range of the individually acceptable VAS level for pain was 4.32 (95% CI: 3.98; 4.67) (arrow in Figure 3), which was below the range of the initial VAS level (P < 0.001). At I2, both levels did not differ, and 47.1% of the patients had reached their individually acceptable VAS level; at I3, this was true still for 41.4% (Figure 3). Compared to session 1, VAS was reduced at sessions 5 and 10 before and after treatment (Table 6).


Safety and effectiveness of vibration massage by deep oscillations: a prospective observational study.

Kraft K, Kanter S, Janik H - Evid Based Complement Alternat Med (2013)

Pain (visual analogue scale (VAS)) before treatment (I1), 2–4 weeks after the last treatment session (I2), and 2 months after I2 (I3); mean and 95% confidence interval (95% CI); I1 versus I2 or versus I3: *P < 0.001; arrow and lines indicate 95% CI of the individually acceptable pain level of the patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3814103&req=5

fig3: Pain (visual analogue scale (VAS)) before treatment (I1), 2–4 weeks after the last treatment session (I2), and 2 months after I2 (I3); mean and 95% confidence interval (95% CI); I1 versus I2 or versus I3: *P < 0.001; arrow and lines indicate 95% CI of the individually acceptable pain level of the patients.
Mentions: Compared to I1, mean VAS score (pain) at I2 was reduced by 28.2% and at I3 by 18.8% (P < 0.001; Figure 3, Table 7). The patients' distribution according to the pain severity categories was mild (17.1%), moderate (25.7%), severe (35.7%), and very severe (21.5%) at I1; at I2 and I3, a shift to lower categories was shown (Table 5). At I1, the range of the individually acceptable VAS level for pain was 4.32 (95% CI: 3.98; 4.67) (arrow in Figure 3), which was below the range of the initial VAS level (P < 0.001). At I2, both levels did not differ, and 47.1% of the patients had reached their individually acceptable VAS level; at I3, this was true still for 41.4% (Figure 3). Compared to session 1, VAS was reduced at sessions 5 and 10 before and after treatment (Table 6).

Bottom Line: Primary outcome parameters were safety and tolerability (5-level Likert scale (1 = very good)) (after each treatment session and at control visit).Tolerability was rated as 1.8 (95% confidence interval: 1.53; 2.07).In conclusion, deep oscillation massage is safe and well tolerated in patients with FMS and might improve symptoms and quality of life rather sustained.

View Article: PubMed Central - PubMed

Affiliation: Chair of Complementary Medicine, Center of Internal Medicine, Rostock University Medicine, Ernst-Heydemann-Straße 6, 18057 Rostock, Germany.

ABSTRACT
The objective of this study is to assess the safety of treatment with vibration massage using a deep oscillation device and the effects on symptom severity and quality of life in patients with primary fibromyalgia syndrome (FMS). Outpatients with FMS performed an observational prospective study with visits 2-4 weeks after the last treatment (control) and after further 2 months (follow-up). Patients were treated with 10 sessions of 45 min deep oscillation massage, 2/week. Primary outcome parameters were safety and tolerability (5-level Likert scale (1 = very good)) (after each treatment session and at control visit). Secondary outcome parameters were symptom severity (Fibromyalgia Impact Questionnaire (FIQ), pain) and quality of life (SF-36). Seventy patients (97.1% females) were included. At control visit, 41 patients (58.6%) reported 63 mild and short-lasting adverse events, mainly worsening of prevalent symptoms such as pain and fatigue. Tolerability was rated as 1.8 (95% confidence interval: 1.53; 2.07). Symptoms and quality of life were significantly improved at both control and follow-up visits (at least P < 0.01). In conclusion, deep oscillation massage is safe and well tolerated in patients with FMS and might improve symptoms and quality of life rather sustained.

No MeSH data available.


Related in: MedlinePlus